After Eli Lilly, Novo Nordisk to reduce insulin prices in US

After Eli Lilly, Novo Nordisk will cut US list prices for several insulin drugs by up to 75% next year. Novo will reduce the list price of NovoLog insulin by 75% and for Novolin and Levemir by 65%. The moves follow President Joe Biden's Inflation Reduction Act last year that capped insulin prices for Medicare recipients at $35 per month.